A Lifeline for Australians Battling a Debilitating Disease: Ultomiris® Now PBS-Listed for Generalised Myasthenia Gravis
March 2, 2026 – In a significant development for Australians living with the rare and debilitating condition generalised myasthenia gravis (gMG), Ultomiris® (ravulizumab rch) is now available on the Pharmaceutical Benefits Scheme (PBS). This announcement, made by Health and Aged Care Minister Mark Butler MP at the World Rare Disease Day event, marks a crucial step forward in accessible treatment options for this challenging disease.
But here's where it gets controversial... While Ultomiris offers hope, its use comes with a serious warning about increased risk of life-threatening meningococcal infections. This raises important questions about balancing the benefits of treatment against potential risks, a dilemma faced by both patients and healthcare providers.
A Crippling Condition with a New Treatment Option
Generalised myasthenia gravis is a chronic autoimmune disease that wreaks havoc on the neuromuscular system, leading to severe muscle weakness and loss of function. Imagine struggling with simple tasks like speaking clearly, swallowing food, or even keeping your eyelids open. These are the daily realities for the estimated 3,000 Australians living with gMG. The disease often begins with seemingly minor symptoms like slurred speech, double vision, and droopy eyelids, but progresses to more severe issues like extreme fatigue, difficulty swallowing, choking, and respiratory distress.
And this is the part most people miss... gMG disproportionately affects women under 40 and men over 60, though it can strike at any age, even in childhood.
Ultomiris, developed by Alexion, AstraZeneca Rare Disease, offers a new treatment avenue for:
- Those with acute, severe gMG at high risk of rapid deterioration.
- Short-term disease control while other treatments take effect.
- Patients who haven't responded to, are intolerant of, or have contraindications to other therapies.
Expert Perspective: A Welcome Addition to the Arsenal
Associate Professor Stephen Reddel, a leading Australian neurologist and gMG expert, highlights the impact of the disease: "Generalised myasthenia gravis can be incredibly debilitating, making even the simplest daily tasks a challenge. In severe cases, it can affect breathing, swallowing, and movement, leading to potentially life-threatening complications. Having new treatments like Ultomiris available gives patients and clinicians more options to manage this complex disease."
Patient Advocacy: A Long-Awaited Victory
Susan White, Chairperson of Myasthenia Alliance Australia, expressed relief and gratitude: "This is a momentous day for myasthenia gravis patients. Access to Ultomiris through the PBS has been a long journey, and we thank the government for making this innovative treatment accessible to Australians."
A Commitment to Rare Diseases
Nicole Gaupset, General Manager of Alexion Australasia, emphasized their dedication: "At Alexion, we are committed to bringing innovative treatments to patients with rare diseases. We are thrilled that Ultomiris will now be available through the PBS, offering hope to Australians living with gMG."
Important Considerations and Safety Information
While Ultomiris represents a significant advancement, it's crucial to remember that it's not without risks. The medication carries a serious warning about increased susceptibility to meningococcal infections, which can be life-threatening. Patients must be vaccinated against meningococcal disease at least two weeks before starting treatment, and closely monitored for any signs of infection.
The Debate: Weighing Risks and Benefits
The introduction of Ultomiris sparks a necessary conversation about the delicate balance between the potential benefits of a powerful treatment and the inherent risks involved. How do we ensure informed consent when faced with such complex decisions? How do we support patients in navigating these choices? These are questions that demand ongoing dialogue and collaboration between patients, healthcare professionals, and policymakers.
Looking Ahead
The listing of Ultomiris on the PBS is a significant step forward in the fight against gMG. It offers renewed hope for patients and their families, while also highlighting the ongoing need for research and innovation in the field of rare diseases. As we celebrate this advancement, let's continue to advocate for increased awareness, improved diagnostics, and access to life-changing treatments for all those affected by rare and debilitating conditions.
What are your thoughts? Do you think the benefits of Ultomiris outweigh the risks? How can we best support patients facing complex treatment decisions? Share your perspectives in the comments below.
For more information on Ultomiris, please consult the full Product Information and Consumer Medicine Information available at the provided links.
This article is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment recommendations.
